Losartan Potassium
Product Images NDC 53808-0896

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 53808-0896). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by State Of Florida Doh Central Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label Image For 25mg (25mg Qualitest)

Label Image For 25mg (25mg Qualitest)
Label for Losartan Potassium 25 mg tablets, quantity 30, prescription only. The label includes lot and expiration details, barcodes, and indicates packaging by the DOH Central Pharmacy in Tallahassee, FL.*
FDA Label Image

Label Image For 50mg (50mg Qualitest)

Label Image For 50mg (50mg Qualitest)
Label for Losartan Potassium 50 mg tablets indicating prescription use (RX Only). The label shows a quantity of 100 tablets and includes lot number, expiration date, and packaging by Florida DOH Central Pharmacy in Tallahassee, FL. A barcode and UPC code are also visible.*
FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
A line graph comparing the percentage of patients with primary endpoint events over study months between Atenolol and Losartan Potassium Tablets. The graph shows time on the x-axis (0 to 66 months) and percentage of patients on the y-axis (0 to 16%), illustrating risk reduction associated with Losartan Potassium Tablets.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
A line graph comparing the number of patients with fatal or nonfatal strokes over a 66-month study period for Atenolol and Losartan Potassium Tablets. The graph shows a lower incidence in the Losartan Potassium group, indicating an adjusted risk reduction of 25% with statistical significance (p=0.001).*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
A figure titled 'Primary Endpoint Events within Demographic Subgroups' presenting comparative hazard ratios for Losartan potassium tablets versus Atenolol on primary composite events and stroke (fatal/non-fatal). The chart breaks down event rates and hazard ratios by demographic factors including age, gender, race, ischemic heart status (ISH), diabetes, and history of cardiovascular disease (CVD), with visual markers indicating favor towards either drug.*
FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
A line graph comparing the percentage of patients experiencing an event over 48 months for Losartan Potassium tablets versus placebo. The graph shows a steady increase in events over time, with Losartan Potassium consistently having a lower percentage of patients affected. Risk reduction and p-value are noted on the graph.*
FDA Label Image

Structure-losartan Potassium (Structure)

Structure-losartan Potassium (Structure)
Chemical structure of Losartan Potassium showing the molecular arrangement including a tetrazole ring, chlorobenzene ring, and other functional groups characteristic of this active ingredient.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.